close
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform
AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens. ©KU Leuven - Rob Stevens
News

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

AstriVax will draw on technology developed at the KU Leuven Rega Institute (Belgium) to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various pathogens.

Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs. The company will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens. The funding round was led by V-Bio Ventures and Fund+. The other investors are Flanders Future TechFund, Thuja Capital, Ackermans & van Haaren, Mérieux Equity Partners (via OMX Europe Venture Fund), BNP Paribas Fortis Private Equity, and the KU Leuven Gemma Frisius Fund. AstriVax will use the seed capital to bring their first thermostable yellow fever vaccine to the clinical development stage and to further develop their pipeline vaccine candidates – one to prevent rabies and one to treat chronic hepatitis B. The company will also continue to build its innovative, first-in-class plug-and-play vaccine platform based on the ground-breaking work of co-founders Professor Johan Neyts and Kai Dallmeier, PhD, from the KU Leuven Rega Institute. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology, such as the duration of protection and the ease of production. As the vaccines will no longer require a strict cold chain, getting them from the factory to patients will be easier, even in tropical and subtropical regions.

AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens. ©KU Leuven - Rob Stevens

AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.
©KU Leuven – Rob Stevens

25/08/2022


COMMENTS ARE OFF THIS POST